Skip to content
10-K

Annual Report

Tempest Therapeutics, Inc. TPST

0001193125-26-130490

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 14.34M sh
Shares Diluted FY 2025 · Dec 31, 2025 4.15M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 2.15M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $435K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$26.82M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$33.03M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.71M
Cash And Equivalents FY 2025 · Dec 31, 2024 $30.27M
Stockholders Equity FY 2025 · Dec 31, 2025 $6.67M
Stockholders Equity FY 2025 · Dec 31, 2024 $19.13M
Stockholders Equity FY 2025 · Dec 31, 2023 $26.77M
Current Liabilities FY 2025 · Dec 31, 2025 $3.31M
Current Liabilities FY 2025 · Dec 31, 2024 $14.22M
Total Liabilities FY 2025 · Dec 31, 2025 $10.26M
Total Liabilities FY 2025 · Dec 31, 2024 $22.36M
Current Assets FY 2025 · Dec 31, 2025 $8.27M
Current Assets FY 2025 · Dec 31, 2024 $31.47M
Total Assets FY 2025 · Dec 31, 2025 $16.93M
Total Assets FY 2025 · Dec 31, 2024 $41.49M
Eps Diluted FY 2025 · Dec 31, 2025 −$6.33
Eps Diluted restated FY 2025 · Dec 31, 2024 −$19.50
Eps Basic FY 2025 · Dec 31, 2025 −$6.33
Eps Basic restated FY 2025 · Dec 31, 2024 −$19.50
Net Income FY 2025 · Dec 31, 2025 −$26.26M
Net Income FY 2025 · Dec 31, 2024 −$41.84M
Operating Income FY 2025 · Dec 31, 2025 −$26.58M
Operating Income FY 2025 · Dec 31, 2024 −$42.03M